UConn Health
Welcome,         Profile    Billing    Logout  
 52 Trials 
155 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Metersky, Mark
NCT05079620: Early Antibiotics After Aspiration in ICU Patients

Terminated
4
5
US
Ceftriaxone, Amoxicillin clavulanic acid, Augmentin, Cefepime, Vancomycin, Levofloxacin
UConn Health
Aspiration, Aspiration Pneumonia
04/24
04/24
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

Terminated
2
41
US
Placebo, Dipyridamole Tablets, Persantine
UConn Health
COVID-19 Pneumonia, Vascular Complications
03/22
04/22
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
Litt, Mark D
NCT05862870: TMD Online Program for Pain Management

Completed
N/A
21
US
painTRAINER
UConn Health, National Institute of Dental and Craniofacial Research (NIDCR)
TMD/Orofacial Pain
08/23
08/23
NCT04376333: Individualized Assessment and Treatment for TMD

Recruiting
N/A
160
US
Cognitive-Behavioral Treatment, CBT, Individualized Assessment and Treatment Program, IATP, Standard Conservative Care, STD
UConn Health, National Institute of Dental and Craniofacial Research (NIDCR)
Temporomandibular Joint Disorders, Orofacial Pain
01/25
06/26
Brewer, Molly A
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
Oncken, Cheryl A
NCT04098302: Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

Completed
2/3
180
US
Dutasteride Capsules, Avodart, Placebo Capsules, inactive placebo
UConn Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
06/24
06/24
Celi, Francesco S
NCT06731764: Novel Approaches to the Treatment of Hypothyroidism

Recruiting
2/3
90
US
Levothyroxine, LT4, Levothyroxine/Liothyronine once daily, LT4/LT3, Levothyroxine/Liothyronine twice daily
UConn Health
Hypothyroidism
01/27
06/27
NCT04782856: Energy Metabolism in Thyroidectomized Patients

Completed
2
13
US
Levothyroxine, L-Thryroxine, Liothyronine, Cytomel, Placebo, Dextrose
Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
04/23
04/23
Covault, Jonathan
NCT04098302: Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

Completed
2/3
180
US
Dutasteride Capsules, Avodart, Placebo Capsules, inactive placebo
UConn Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
06/24
06/24
Liang, Bruce T
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

Terminated
2
41
US
Placebo, Dipyridamole Tablets, Persantine
UConn Health
COVID-19 Pneumonia, Vascular Complications
03/22
04/22
NCT04321512: Study of Circulating Monocytes in Patients With Ischemic Vascular Disease

Recruiting
N/A
300
US
There is no intervention given to the subjects
UConn Health
Myocardial Infarction, Stroke, Ischemic, Ischemia
02/25
02/25
NCT00762333: Circulating Markers for Ischemic Heart Disease

Recruiting
N/A
550
US
UConn Health
Myocardial Infarction, Ischemia, Congestive Heart Failure
03/26
03/26
NCT00762008: Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

Recruiting
N/A
500
US
UConn Health, CT Department of Public Health
Acute Decompensated Heart Failure, Heart Failure
09/25
09/25
Singh, Hardeep
NCT05929755: Depo-Medrol on Psoas After LLIF

Recruiting
4
80
US
Depo-Medrol, Gel-Flow NT
Hardeep Singh, Society for Minimally Invasive Spine Surgery
Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
08/25
05/27
NCT04166240: Measuring and Improving the Safety of Test Result Follow-Up

Completed
N/A
46
US
SAFER TRACKS Intervention
VA Office of Research and Development, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Birmingham Veterans Affairs Health Care System
Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer, Hepatocellular Cancer
04/22
09/23
Mortensen, Eric M
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

Terminated
2
41
US
Placebo, Dipyridamole Tablets, Persantine
UConn Health
COVID-19 Pneumonia, Vascular Complications
03/22
04/22
Kwon, Oh Sang
Mito-LUTS, NCT06351683: Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Recruiting
2
50
US
MitoQ (mitoquinol mesylate), MitoQ, Placebo
Iman Al-Naggar, PhD, National Institute on Aging (NIA), American Urological Association, Urology Care Foundation, Claude D. Pepper Older Americans Independence Center (OAIC)
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
12/25
12/25
Mito-Frail, NCT06027554: The Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Recruiting
2
60
US
Mitoquinone Mesylate, Placebo capsule
UConn Health, National Institute on Aging (NIA), University of Connecticut
Frailty, Mild Cognitive Impairment, Aging
09/25
07/27
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT04740346: Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)

Recruiting
N/A
886
RoW
Computed tomography, Chest X-ray, and blood test
National Cancer Center, Korea, Korea Health Industry Development Institute
Gastric Cancer, Recurrence, Quality of Life
06/26
06/26
Wallace, Paul
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Active, not recruiting
2
72
Europe, Canada, US, RoW
Placebo/Daxdilimab, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
09/25
09/25
NCT04807179: Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars

Active, not recruiting
N/A
39
US
Experimental: RF Device Arm
Cynosure, Inc.
Acne Scars
08/24
08/24
Weinstein, David A
NCT05399641: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Completed
3
150
US
Ibrexafungerp
Scynexis, Inc.
Vulvovaginal Candidiasis
05/23
08/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Uribe, Flavio
NCT05780788: Characterizing Orthodontic Tooth Movement With Photographic Scans

Recruiting
N/A
30
US
Monitoring Tooth Movement
UConn Health
Canine Retraction
07/24
07/24
NCT06668194: Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome

Recruiting
N/A
40
US
Light Force (150g Niti Coil), Heavy Force (400 g Niti coil)
UConn Health, Charles Burstone Foundation
Tooth Crowding
10/27
04/28
Bulsara, Ketan R
iVAST , NCT01996436: The Intra-arterial Vasospasm Trial

Recruiting
4
330
US
Nicardipine, Cardene, Verapamil, Nicardipine + Verapamil + Nitroglycerin
Peng Roc Chen, MD, Yale University, Thomas Jefferson University, University of Illinois at Chicago, Wake Forest University Health Sciences, Temple University, Geisinger Clinic, Northwell Health, University of Michigan, Lenox Hill Hospital, Weatherhead Foundation
Cerebral Vasospasm
08/24
12/24
Moss, Isaac
NCT05929755: Depo-Medrol on Psoas After LLIF

Recruiting
4
80
US
Depo-Medrol, Gel-Flow NT
Hardeep Singh, Society for Minimally Invasive Spine Surgery
Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
08/25
05/27
Tannenbaum, Susan
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
Lin, Michael
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Recruiting
2
60
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
02/25
06/25
NCT06587828: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease

Recruiting
N/A
300
US
Companion blood samples with procedure
TScan Therapeutics, Inc.
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease, Birdshot Chorioretinitis
01/25
06/25
Tennen, Howard
NCT05862870: TMD Online Program for Pain Management

Completed
N/A
21
US
painTRAINER
UConn Health, National Institute of Dental and Craniofacial Research (NIDCR)
TMD/Orofacial Pain
08/23
08/23
Ibrahim, Omar
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
TARGET, NCT04182815: Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung

Completed
N/A
691
Canada, US, RoW
Robotic assisted bronchoscopy, Robotic assisted bronchoscopy with Monarch platform
Auris Health, Inc.
Pulmonary Nodule, Lung Cancer
12/23
12/23
NCT06307691: Clinical and Radiographic Evaluation of Immediate Implant Placement Using Osseodensification Versus Traditional Drilling Protocol

Recruiting
N/A
26
RoW
Conventional drilling, Osseodensification drilling
Cairo University
Implant Complication
12/25
12/26
NCT06108765: Acute Kidney Injury in Poly Trauma Patients

Not yet recruiting
N/A
100
NA
Assiut University
Kidney Injury
11/24
12/24
Zajac, Kristyn
NCT03768986: A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

Active, not recruiting
N/A
334
US
Standard referral for HIV testing, Online risk reduction training, Reinforcement
UConn Health, National Institute on Minority Health and Health Disparities (NIMHD)
HIV, HIV Testing, Women, Contingency Management
12/24
12/24
P2P, NCT05374395: Enhancing Substance Use Treatment Services to Decrease Dropout and Improve Outpatient Treatment Utilization in Emerging Adults

Active, not recruiting
N/A
11
US
Peer Recovery Support-Delivered Dropout Prevention enhancement
UConn Health, Oregon Social Learning Center, University of Texas at Austin
Substance Use Disorders
10/26
02/27
Lu, Jun
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Recruiting
2
240
RoW
Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight
Suzhou Alphamab Co., Ltd.
Knee Arthroplasty, Total
12/25
04/26
GMCAII, NCT06221683: Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting
2
500
RoW
Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT
Children's Hospital of Soochow University
AML, Childhood, Acute Myeloid Leukemia
12/28
12/29
NCT06316960: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting
2
50
RoW
Avapritinib, AYVAKIT, Azacitidine Injection, Azacitidine, Decitabine Injection, Decitabine, Idarubicin Hydrochloride, Idarubicine, Cytarabine, CYTOSAR, Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection
Children's Hospital of Soochow University
AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia, C-KIT Mutation
03/26
03/27
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Active, not recruiting
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
NCT05962450: Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Recruiting
2
84
RoW
iNKT Cells, Vα24+ T Cells, PD-1, Regorafenib
Beijing YouAn Hospital, Beijing Gene Key Life Technology Co., Ltd.
Hepatocellular Carcinoma
08/25
08/25
NCT06456138: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Not yet recruiting
1/2
60
RoW
Trametinib, Anlotinib, Tislelizumab
Shanghai Chest Hospital, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis
KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
06/26
12/28
NCT06278675: Multiple Study of Electroaccpuncture in ARDS

Not yet recruiting
N/A
264
RoW
Acupuncture needles
Nanjing University of Traditional Chinese Medicine
Acute Respiratory Distress Syndrome, Sepsis
06/26
12/26
NCT06777485: China Liver Cancer Clinical Registry Cohort Database

Recruiting
N/A
10000
RoW
Procedure/Surgery treatment, Anti-Tumor Drugs
Anhui Provincial Hospital
Liver Cancer
01/35
01/35
NCT05449106: Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT

Recruiting
N/A
200
RoW
Beijing Tiantan Hospital, Beijing Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Zhengzhou University
Brain Arteriovenous Malformations
05/27
05/32
Kuchel, George
FluVax3, NCT05518500: A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Recruiting
4
75
US
Flu Vaccine (Year 1), Fluzone® Quadrivalent High-Dose, Flu Vaccine (Year 2), FLUAD, Flu Vaccine (Year 3), Flublok Quadrivalent
The Jackson Laboratory, UConn Health, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID)
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
12/26
12/26
NCT02938923: Starting a Testosterone and Exercise Program After Hip Injury

Completed
3
129
US
Testosterone, T, Placebo gel, P, Supervised exercise training, EX, Home exercise program, EUC, Health Education Modules
Washington University School of Medicine, University of Maryland, Baltimore, University of Colorado, Denver, The University of Texas Medical Branch, Galveston, Johns Hopkins University, Harvard University, University of Connecticut, University of Utah, University of Pittsburgh Medical Center
Hip Fracture, Frailty, Sarcopenia
08/23
11/23
Mito-LUTS, NCT06351683: Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Recruiting
2
50
US
MitoQ (mitoquinol mesylate), MitoQ, Placebo
Iman Al-Naggar, PhD, National Institute on Aging (NIA), American Urological Association, Urology Care Foundation, Claude D. Pepper Older Americans Independence Center (OAIC)
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
12/25
12/25
Mito-Frail, NCT06027554: The Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Recruiting
2
60
US
Mitoquinone Mesylate, Placebo capsule
UConn Health, National Institute on Aging (NIA), University of Connecticut
Frailty, Mild Cognitive Impairment, Aging
09/25
07/27
Andemariam, Biree
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
NCT02306993: Sickle Cell Hemoglobinopathies and Bone Health

Active, not recruiting
N/A
45
US
Healthy volunteers without SCT, Healthy volunteers with SCT, Volunteers with SCD
UConn Health
Sickle Cell Disease, Sickle Cell Trait
12/25
12/25
NCT06743113: Hypoxic Red Blood Cells in Sickle Cell Anemia

Not yet recruiting
N/A
48
US
Hemanext ONE System, Conventional RBCs
Hemanext, Emory University, University of Connecticut, University of Pittsburgh Medical Center, Johns Hopkins All Children's Hospital, Johns Hopkins University
Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
02/28
06/28
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

Terminated
N/A
262
US
Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta®
Pfizer, Pfizer
Sickle Cell Disease
10/24
10/24
Vaziri, Haleh
NCT05195970: Walnuts and Colon Health

Recruiting
N/A
200
US
Walnuts
UConn Health, National Institutes of Health (NIH), National Cancer Institute (NCI), Weill Medical College of Cornell University, University of Connecticut, California Walnut Commission, Spanish National Research Council, University of Florida
Colorectal Cancer, Diet Habit
12/25
12/26
BIRK, JOHN
NCT05195970: Walnuts and Colon Health

Recruiting
N/A
200
US
Walnuts
UConn Health, National Institutes of Health (NIH), National Cancer Institute (NCI), Weill Medical College of Cornell University, University of Connecticut, California Walnut Commission, Spanish National Research Council, University of Florida
Colorectal Cancer, Diet Habit
12/25
12/26
Brugge, Doug
HAFTRAP, NCT04279249: Home Air Filtration for Traffic-Related Air Pollution

Completed
N/A
156
US
HEPA Air Filtration, Sham HEPA Air Filtration
UConn Health, Somerville Transportation Equity Partnership, Inc., Tufts University, Olin College of Engineering, Welcome Project Inc, National Institute of Environmental Health Sciences (NIEHS)
Cardiovascular Risk Factor, Blood Pressure
06/24
06/24
Thurlow, Sheila
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

Terminated
2
41
US
Placebo, Dipyridamole Tablets, Persantine
UConn Health
COVID-19 Pneumonia, Vascular Complications
03/22
04/22
Kenyon-Pesce, Lisa
FluVax3, NCT05518500: A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

Recruiting
4
75
US
Flu Vaccine (Year 1), Fluzone® Quadrivalent High-Dose, Flu Vaccine (Year 2), FLUAD, Flu Vaccine (Year 3), Flublok Quadrivalent
The Jackson Laboratory, UConn Health, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID)
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
12/26
12/26
Mito-LUTS, NCT06351683: Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Recruiting
2
50
US
MitoQ (mitoquinol mesylate), MitoQ, Placebo
Iman Al-Naggar, PhD, National Institute on Aging (NIA), American Urological Association, Urology Care Foundation, Claude D. Pepper Older Americans Independence Center (OAIC)
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
12/25
12/25
Ali, Quratulain
ARGUS, NCT04462770 / 2021-003425-30: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Recruiting
2
100
Europe, Canada, US, RoW
EPX-100 (clemizole HCl), Placebo
Epygenix, Harmony Biosciences, LLC
Dravet Syndrome
04/26
05/26
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
Fetter, Ruth
NCT03959826: Promoting Employment in Persons Living With HIV/AIDS

Recruiting
N/A
144
US
activity contracting, contingency management for activity completion
UConn Health, National Institute on Drug Abuse (NIDA)
Unemployment, HIV
01/25
01/25
NCT03768986: A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

Active, not recruiting
N/A
334
US
Standard referral for HIV testing, Online risk reduction training, Reinforcement
UConn Health, National Institute on Minority Health and Health Disparities (NIMHD)
HIV, HIV Testing, Women, Contingency Management
12/24
12/24
Peth, NCT04064463: Dual Reinforcement Contingency Management for Alcohol Use Disorders

Recruiting
N/A
150
US
Standard care, Contingency management
UConn Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Contingency Management
05/25
05/25
P2P, NCT05374395: Enhancing Substance Use Treatment Services to Decrease Dropout and Improve Outpatient Treatment Utilization in Emerging Adults

Active, not recruiting
N/A
11
US
Peer Recovery Support-Delivered Dropout Prevention enhancement
UConn Health, Oregon Social Learning Center, University of Texas at Austin
Substance Use Disorders
10/26
02/27
Becker, Kevin
ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting
3
1210
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation, Inspection, Visual Inspection, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
12/25
12/25
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
ALCHEMIST, NCT02201992: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An Treatment Trial)

Recruiting
3
168
US, RoW
Clinical Observation, Crizotinib, MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
05/36
05/36
NCT03866382: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
2
314
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
02/25
02/25
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Recruiting
N/A
8300
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
09/26
09/26
Mead, Erin L
NCT04487470: Impact of Cigar Flavor in Dual Users

Recruiting
N/A
145
US
Flavored filtered cigars, Unflavored filtered cigars
UConn Health, National Institute on Drug Abuse (NIDA)
Tobacco Use Disorder
05/24
05/24
Bartley, Jenna
NCT02938923: Starting a Testosterone and Exercise Program After Hip Injury

Completed
3
129
US
Testosterone, T, Placebo gel, P, Supervised exercise training, EX, Home exercise program, EUC, Health Education Modules
Washington University School of Medicine, University of Maryland, Baltimore, University of Colorado, Denver, The University of Texas Medical Branch, Galveston, Johns Hopkins University, Harvard University, University of Connecticut, University of Utah, University of Pittsburgh Medical Center
Hip Fracture, Frailty, Sarcopenia
08/23
11/23
Mito-LUTS, NCT06351683: Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Recruiting
2
50
US
MitoQ (mitoquinol mesylate), MitoQ, Placebo
Iman Al-Naggar, PhD, National Institute on Aging (NIA), American Urological Association, Urology Care Foundation, Claude D. Pepper Older Americans Independence Center (OAIC)
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
12/25
12/25
TAKEOFF, NCT06645847: Targeting Aging with a Ketone Ester for Function in Frailty

Not yet recruiting
N/A
600
US
Ketone ester, Placebo Comparator: Non-ketone placebo
Buck Institute for Research on Aging, Ohio State University, University of Connecticut
Frail Elderly, Aging, Immune Function, Muscle Function
11/27
02/28
Laquer, Vivian
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
186
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting
3
292
Europe, Japan, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/24
12/24
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Recruiting
3
472
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
05/25
02/26
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
 

Download Options